Trial reportKorean journal of radiology2021
Radiofrequency Ablation Using a Separable Clustered Electrode for the Treatment of Hepatocellular Carcinomas: A Randomized Controlled Trial of a Dual-Switching Monopolar Mode Versus a Single-Switching Monopolar Mode.
Trial report in Korean journal of radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07192172 (Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Trans-arterial Chemoembolization), which is not on this map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Enhanced Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma Post-Trans-arterial Chemoembolization: A Prospective Study Using Twin Internally Cooled-Perfusion Electrodes
Who cites it
10 citing papers in PubMed, 19 citations in OpenAlex.
- Incremental high power radiofrequency ablation with multi-electrodes for small hepatocellular carcinoma: a prospective study.BMC gastroenterology · 2024Trial
- Enhanced radiofrequency ablation for recurrent hepatocellular carcinoma post-transarterial chemoembolization: a prospective study utilizing twin internally cooled-perfusion electrodes.Journal of liver cancer · 2025Article
- Mechanisms of rapid tumor progression after insufficient radiofrequency ablation of hepatocellular carcinoma.Frontiers in cell and developmental biology · 2025Review
- Microwave ablationJHEP reports : innovation in hepatology · 2025Article
- Anatomical ablation for small hepatocellular carcinomas using multiple applicators: a preliminary study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Review
- Review
- Research Highlight: How to Use Technical and Oncologic Outcomes of Image-Guided Tumor Ablation According to Guidelines by Society of Interventional Oncology and DATECAN?Korean journal of radiology · 2022Article
- Mistakes to Avoid for Accurate and Transparent Reporting of Survival Analysis in Imaging Research.Korean journal of radiology · 2021Article
- Tumor-killing nanoreactors fueled by tumor debris can enhance radiofrequency ablation therapy and boost antitumor immune responses.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveThis study aimed to prospectively compare the efficacy, safety, and mid-term outcomes of dual-switching monopolar (DSM) radiofrequency ablation (RFA) to those of conventional single-switching monopolar (SSM) RFA in the treatment of hepatocellular carcinoma (HCC). MATERIALS AND
methodsThis single-center, two-arm, parallel-group, randomized controlled study was approved by the Institutional Review Board. Written informed consent was obtained from all patients upon enrollment. A total of 80 patients with 94 HCC nodules were randomized into either the DSM-RFA group or SSM-RFA group in a 1:1 ratio, using a blocked randomization method (block size 2). The primary endpoint was the minimum diameter of the ablation zone per unit time. The secondary endpoints included other technical parameters, complication rate, technique efficacy, and 2-year clinical outcomes.
resultsSignificantly higher ablation energy per unit time was delivered to the DSM-RFA group than to the SSM-RFA group (1.7 ± 0.2 kcal/min vs. 1.2 ± 0.3 kcal/min;
conclusionAlthough DSM-RFA using a separable clustered electrode delivers higher ablation energy than SSM-RFA, its effectiveness failed to show superiority over SSM-RFA in the treatment of HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.